Breast cancer is a common female cancer occurring globally, and it is the most common cancer among Japanese women. Interestingly, it’s more likely to affect middle-aged women in Japan than older women, which is different from most other cancers①. There’s been a worldwide rise in breast cancer cases, especially noticeable in Japan too. This increase […]
The Way Forward for Decentralise Clinical Trials in Japan: As Decentralized clinical trials, brings participants the opportunity of participating in a clinical trial from the ease of their home or a local healthcare facility which is different to the traditional clinical trial site location far from the participant’s home. 3H, a Home-based clinical trial leader […]
Uchiken; 3H`s owned Home Nursing station achieves accreditation as Certified Home Nursing Service Provider, Enabling Enhanced Access to Clinical Trials for Patients 3H Medi solution Co., Ltd. Tokyo, Toshima-ward; represented by CEO Hirotaka Takizawa proudly announces its recent accreditation as a designated home nursing service provider. This accreditation, obtained on November 1, 2023, applies to […]
Initiating the provision of analysis information on differences in drug effects for each genetic polymorphism for contributing to the advancement of drug development and improvement in treatment options and treatment satisfaction for patients. 3H Medi Solution Inc. (Toshima-ku, Tokyo; CEO: Hirotaka Takizawa) and Genequest Inc. (Minato-ku, Tokyo; CEO: Osamu Iwata) have jointly conducted an analysis […]
When conducting clinical trials, it is important to have a well-constructed recruitment pathway. Clinical trials which fail to meet the enrolment target could have substantial delays as well as have small sample sizes which could decrease the study power and lead to early termination. As many as 85% of clinical trials fail to meet recruitment […]
Recruitment remains a key challenge in clinical trial conduct. With the clinical trial protocols becoming more complex with stringent inclusion and exclusion criteria, it makes it more difficult to enrol and retain participants in clinical trials through traditional recruitment strategies. Decentralise clinical trials on the other hand have redefined successful recruitment, facilitating better subject engagement […]
The world is transitioning into the information age in healthcare and modern digital health technologies have a lot to offer in optimising clinical trial conduct. The advent of wearable medical devices has enabled collection of multi-dimensional subject data. This has enabled de-centralisation of clinical trial conduct. 3H has been agile to adopt the latest information […]
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; Representative Director, President, Gyo Sagara; “ONO”) and 3H Clinical Trial Inc. (Tokyo, Japan; Representative Director, Hirotaka Takizawa; “3H”) announced that the companies developed and started providing “Fukusapo”, an adverse drug reaction (ADR) management supporting tool for patients as from today, aiming at the ADR management in patients receiving the […]
Clinical trial conduct is a substantial investment requiring the right mix of resources and time. With the pharmaceutical industry facing many challenges in the Western world due to escalating costs and challenges in meeting the recruitment and retention of subjects, there is a trend in navigating clinical trial options in the Asian continent. Contract research […]
© 2024 · Your Website. Theme by HB-Themes.